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Abstract
AIM
To collect data from joint replacement in inhibitor patients, 
evaluate haemostatic and patient outcomes, and analyse 
the costs.
METHODS
We report our 21-year, single-centre cumulative expe-
rience of 15 joint arthroplasties in six inhibitor patients.
RESULTS
Two low responder inhibitor patients were in the early 
days treated with FVIII, whereas bypassing agents were 
used in the rest of the high responder patients. The 
primary haemostatic outcome was good in 8/15, fair in 
4/15 and poor in 3/15 operations. The overall patient 
outcome, including joint health and patient satisfaction, 
was good in 10/15, fair 4/15 and poor in 1/15. No de-
ep infections were observed. Cost analysis was most 
beneficial in low responders and in two immune-tolerized, 
high responder patients. In all cases, factor replacement 
comprised the main treatment costs.
CONCLUSION
Our experience supports the initial use of bypassing 
agents as well as preoperative immune-tolerance induction 
when possible. Despite the challenges of haemostasis 
and severe joint disease, total joint arthroplasty can reach 
a good outcome, even in inhibitor patients. The risk for 
deep infection might be smaller than previously reported. 
Individual planning, intense multidisciplinary teamwork 
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and execution of operations should be centralised in a 
professional unit. 
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Core tip: There are only few reports including joint art-
hroplasties on inhibitor-positive haemophilia patients. 
Generally the focus is mainly on immediate haemostatic 
outcome leaving the long-term orthopaedic results 
unreported. Our study brings out the importance of long-
term and overall outcome when performing elective 
life-quality surgery. Management of inhibitor patients is 
especially challenging regarding not only the operative 
treatment but also the costs. As the health economic 
analysis of the topic is lacking, we provide new data. 
According to our cost analysis, preoperative immune-
tolerance induction for high responder patients will bring 
cost- and outcome benefit both in surgery and preventing 
postoperative bleeds. 
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INTRODUCTION 
Total joint arthroplasty covered with coagulation factor 
replacement therapy is the treatment of choice in 
severe haemophilic arthropathy when conservative 
treatment has failed. The failure to stabilize the joint 
disease is usually due to the late initiation of secondary 
prophylaxis with replacement therapy. Patients may 
develop inhibitors to their factor replacement therapy 
due to the foreign protein and have thus often missed 
the prophylactic replacement therapy and surgical 
treatment because of the fear of bleeds and the high 
costs of the treatment. In the literature, the inhibitor 
prevalence is around 10% among the adult patient 
population, mainly affected by the earlier treatment 
and availability of immune-tolerance induction (ITI) 
therapy[1-3].
The appropriate replacement therapy depends 
on the patient’s individualized response, which is not 
always similar - nor predictable - at each haemostatic 
challenge or management strategy. The introduction of 
bypassing agents has enabled total joint replacements 
also for high responder inhibitor patients[4]. However, 
the use of these products is costly. 
The reports on joint arthroplasties in inhibitor patients 
are mainly case-based, and established standards of the 
management of these operations are scanty[5-7]. At Orton 
Orthopaedic Hospital of Invalid Foundation, centralised 
operative treatment of haemophilic joint disease 
has been carried out already since the 1970s. The 
haematological and laboratory support has been available 
by Red Cross Transfusion Central from 1957, and from 
2002 also by the Helsinki University Hospital Coagulation 
Disorders unit. The first total hip replacement (THR) 
for a haemophilia patient in Finland was performed in 
1982, and the first knee replacement (TKR) in 1984. 
The first TKR on a patient with recognized inhibitors was 
performed in 1991. We report our cumulative experience 
of 21 years of 15 joint arthroplasties in six haemophilia 
inhibitor patients.
MATERIALS AND METHODS
From 1991 to 2012, six haemophilia patients with 
inhibitors (two low; inhibitor titre < or equal to 5 BU/mL) 
and four high responders; inhibitor titre > 5 IU/mL) 
were operated on (Tables 1 and 2). The 15 surgical 
procedures consisted of seven primary TKRs (in two 
patients, bilateral), one unicondylar knee arthroplasty, 
one glenohumeral replacement, two ankle arthroplasties, 
one THR and three knee revision arthroplasties.
Two patients were low responders (inhibitor titre < 5 
BU/mL). Four patients who had a history of high inhibitor 
titre (> 5 BU/mL) were classified as high responders, but 
the titre immediately prior to surgery was < 5 BU/mL. 
Two high-titre inhibitor patients underwent successful ITI 
as a part of the ObsITI protocol at a later stage (from 
2010 onwards) of the follow-up. Five patients (83%) had 
a history of hepatitis C. One patient also was antibody-
positive for hepatitis B. None of the patients was HIV 
positive.
To manage surgery during the early 1990s, the 
historical peak inhibitor titre, whether low or high (< 
or > 5 BU/mL), dictated the strategy. Traditionally, 
immediately preoperatively in the absence of FVIII 
inhibitory antibodies (i.e., confirmed normal recovery and 
half-life of FVIII), either recombinant or plasma-derived 
FVIII is infused intravenously to secure haemostasis by 
reaching normal FVIII levels (usually 80%-100%). In 
contrast, the presence of inhibitors neutralise FVIII, and 
for the surgery FVIII bypassing agents, either activated 
prothrombin complex concentrate (aPCC, FeibaR) or 
recombinant activated Factor VII (rFVIIa, NovoSeven), 
are the current effective options to maintain surgical 
haemostasis of blood. The specific agent is chosen 
according to the individual bleeding phenotype, history 
and patient weight. Initially, either cryoprecipate or 
a plasma-derived FVIII (pdFVIII) was used in all low 
responders and initially in high responders having a 
preoperative low inhibitor titre, with the objective to 
switch to a bypassing agent once the inhibitor titre 
inclined. Low responders (Patients A and B) were initially 
treated with their standard replacement therapy: 
Cryoprecipitate (AHF-20®, n = 1/8) or coagulation factor 
VIII (pdFVIII, Amofil®, n = 7/8). For the high responder 
patients (C-F), the treatment was either activated 
prothrombin complex concentrate (aPCC, FEIBA®) or 
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recombinant activated factor VIIa (rFVIIa, NovoSeven®). 
In one case, the treatment was started with pdFVIII, but 
changed to aPCC when the inhibitor titre arose. 
The routine blood coagulation tests were monitored 
daily during the FVIII replacement period to capture FVIII: 
C clotting activity or during bypassing therapy to capture 
the possible development of disseminated intravascular 
coagulation (DIC), anaemia or thrombocytopenia. 
Cefuroxime was used as standard antibiotic prophylaxis (or 
clindamycin, in case of allergy).
After TKR, continuous passive motion (CPM) treatment 
was started at the 2nd-7th postoperative day. After THR, 
immediate full body weight bearing was allowed, if the 
blood and haemostatic status supported the decision. 
After ankle arthroplasties, half-weight bearing with walker 
orthosis was recommended for 6-8 wk. After glenohumeral 
arthroplasty, the upper arm was immobilized in an arm 
sling for 4 wk and only passive mobilization for 6 wk was 
allowed. 
Primary haemostatic outcome was considered good 
if the postoperative bleeding did not differ from the 
normal arthroplasty, fair if there were additional bleeds 
and poor if there were massive or repetitive additional 
bleeds that were difficult to manage.
The statistical analysis was carried out using the 
SPSS 20.0, Lead Technologies, Inc. statistical software 
system. For analysis, a paired-samples T-test was used. 
In this study, a P-value < 0.05 (two-sided probability) 
was considered significant.
RESULTS 
Low responders (A and B). Two low inhibitor titre 
patients underwent several operations, the details of 
which are captured in Table 1.
In Patient A, TKR was carried out under cryoprecipitate 
coverage. At three days, the treatment had to be changed 
to pdFVIII when the FVIII: C response started to decline. 
The haemostatic outcome was good.
Three years later, a second primary TKR with pdFVIII 
replacement therapy was performed. The inhibitor 
titre remained low, and the haemostatic and surgical 
outcomes were good. Two years later, the patient 
experienced recurrent knee bleeds at the recent TKR 
site. Three arthroscopical synovectomies were performed 
under pdFVIII replacement, while any vascular anomaly 
was excluded by popliteal angiography[8,9]. After each 
synovectomy, the bleeding tendency decreased tem-
porarily for a few months. Finally, the bleeds ceased with 
Holmium isotope radiosynoviorthesis. Additionally, two 
total ankle arthroplasties were performed successfully 
under pdFVIII coverage with good haemostatic and 
primary outcomes.
Later, the patient underwent revision knee arthro-
plasties due to aseptic loosening of the components. 
Both arthroplasties were performed using rFVIII. After 
Table 1  Main surgical operations in patients (A and B) with the low historical inhibitor titre (< 5 BU/mL)
Patient and operations (model) Haemophilia therapy Primary haemostatic outcome Surgical outcome
A
  TKR (cruciate retaining) Cryo (AHF-20) → pdFVIII Good Good
  TKR (cruciate retaining) pdFVIII Good Good
  Ankle arthroplasty pdfVIII Good Good
  Ankle arthroplasty pdFVIII Good Good
  Knee revision arthroplasty (reconstructive) rFVIII Fair Good
  Knee revision arthroplasty (reconstructive) rFVIII Good Good
B
  Knee hemiarthroplasty (unicondylar) pdFVIII Good Poor
  Revision arthroplasty (cruciate retaining) pdFVIII → rFVIIa Fair Good
In A, six operations and in B, two operations were performed. TKR: Total knee replacement; pdFVIII: Plasma-derived factor VIII; rFVIII: Recombinant 
FVIII.
Table 2  Main surgical operations in the patients (C-F) with the high historical inhibitor titre
Patient and operations  (model) Replacement therapy Primary haemostatic outcome Surgical outcome ROM/pain
C
  TKR bilateral (hinge + posterior stabilised) pdFVIII → aPCC Poor Fair
  THR (uncemented) rFVIII Good Good
D
  TKR bilateral (reconstructive) aPCC→ rFVIIa Fair Fair
E
  TKR (posterior stabilized) aPCC → rFVIIa Poor Good
F
  Glenohumeral hemiarthroplasty rFVIII Good Good
ROM: Range of motion; TKR: Total knee replacement; THR: Total hip replacement; aPCC: Activated prothrombinase complex concentrate.
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the first operation, the patient experienced a knee 
bleed at 8 d while on continuous replacement therapy, 
which was treated with higher dosing of rFVIII. There 
was a temporary rise in the FVIII antibody, but the final 
outcome was good. The second knee operation resulted 
in good haemostatic and overall outcome.
Patient B had experienced only occasional spontaneous 
bleeding episodes. Before the primary operation, he was 
devoid of inhibitor history. He suffered from posttraumatic 
medial knee arthrosis, and unicondylar knee replacement 
was performed with a good haemostatic outcome 
using pdFVIII. However, the patient needed revision 
arthroplasty 9 mo after the primary operation. Next, the 
replacement therapy was started with pdFVIII, and at 12 
d postoperatively, the inhibitor titre raised the replacement 
therapy was switched to rFVIIa with good haemostatic 
outcome (Figure 1).
In conclusion, the two low responder inhibitor patients 
were managed successfully with FVIII concentrate, 
while the inhibitor titre remained low. Individually and 
according to the type of surgery, the FVIII was switched 
to bypassing agents when the inhibitor titre rose. One 
postoperative bleed in association with 8 operations 
occurred without long-term consequences.
High-responders, patients C-F
The surgical details of Patients C-F are presented in Table 
2. In Patient C with bilateral primary knee arthroplasty, 
the preoperative inhibitor titre was < 5 BU/mL, and the 
operation was carried out without complications using 
pdFVIII. At five days when the inhibitor titre rose, however, 
the patient experienced bilateral knee bleeds and aPCC 
was started. The dose (up to 200-250 U/kg) had to be 
increased for several days due to a fair haemostatic 
response. DIC or deep venous thrombosis did not 
develop. After 5.5 years, the patient underwent a 
successful ITI therapy with rFVIII, and a primary THR 
could be performed with rFVIII 6 mo later with good 
haemostatic and surgical outcome. The recovery and 
half-life of rFVIII were appropriate, and the inhibitor did 
not reoccur throughout the early and later follow-up. 
Patient D had bilateral TKR with aPCC as replacement 
therapy. At 8 d the patient experienced a severe knee 
bleed, which ceased with rFVIIa [two doses of 5 mg 
(90 μg/kg iv) at 2 h interval]. Next, aPCC was re-
administered (at 200 IU/kg) but the patient bled with 
regard to the operated knee twice, at days 11 and 14. 
After the third bleed, the replacement therapy was 
carried out with rFVIIa for four days and thereafter with 
sequential aPCC and rFVIIa for two weeks. 
Patient E underwent TKR with aPCC as replacement 
therapy pre- and perioperatively. At two days, he 
suddenly bled a lot (800 mL/30 min) with regard to 
his operated knee. A bolus of 12 mg of rFVIIa (220 
μg/kg) stopped the bleed immediately. The replacement 
therapy was continued with rFVIIa (6 mg every 2 h) for 
several days, and the haemostatic outcome was finally 
optimal.
Patient F had a history of high inhibitor titre and 
successful ITI with rFVIII one year preoperatively. He 
underwent glenohumeral hemiarthroplasty with good 
haemostatic outcome and without an increase of the 
inhibitor titre during the follow-up.
Overall, in 5 operations out of 12, the patients ex-
perienced major bleeds at 2-8 d postoperatively. Albeit 
this initial haemostatic response was either fair or even 
poor in two patients, the joint outcome was good. One 
patient had bilateral knee operation initially managed 
with pdFVIII, during which there was the reactivation of 
the inhibitor and both-sided bleeds occurred. He had the 
poor haemostatic response. However, the complication 
was controlled by switching the therapy to bypassing 
agents. A single bypassing therapy did not necessarily 
manage to control haemostasis, but the switch between 
aPCC and rFVIIa or their sequential use finally secured 
the haemostatic outcome. 
Primary arthroplasties
The mean follow-up for patients with primary TKR (eight 
arthroplasties) was 7.3 years (0.3-20.3, SD 7.6). The 
median age of the patients at the time of the operation 
was 48.4 years (35.4-66.1, SD 10.9). The median hospital 
stay was 19.6 d (10-25, SD 6.1). The range of motion 
(ROM) improved from mean 81.9° flexion to 96.9° (SD 
17.1 and 11.9, P = 0.07) and from mean 21.3° extension 
deficiency to 7.5° (SD 12.7 and 8.4, P = 0.09). One high 
Figure 1  Unicondylar knee replacement and revision arthroplasty.
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responder patient (Patient D) with severe knee flexion 
contracture with bilateral knee arthroplasty had a patellar 
fracture. It was observed at the two-month control and 
treated conservatively with orthosis. No deep infections 
were observed.
The two ankle arthroplasties were performed without 
complications to the same low responder Patient A. The 
patient had severe haemophilic arthropathy without 
significant deformation or bone loss in both ankles, 
and the preoperative walking distance had diminished 
below 500 m. Preoperative ROM in both ankles was 
from neutral position to 20° plantar flexion and primary 
outcome was from 5° dorsiflexion to 30° of plantar 
flexion, respectively. In 6.1 and 7.0 years follow-up 0°-20° 
ROM in plantar flexion of both ankles was observed. 
The patient could stand on his toes, walking ability was 
improved to 2 km and both ankles were pain-free. 
Radiologically, the components were in good position 
without signs of loosening or other complications.
The total hip arthroplasty for the high responder 
Patient C with a preoperative successful ITI was per-
formed with an excellent haemostatic and primary 
outcome. At the 2-mo follow-up, the patient had a pain-
free joint and ROM 0°-90° extension-flexion, 20° rotation 
and 40° abduction. The radiographic control showed a 
good position of the prosthesis. 
The high responder Patient F with glenohumeral 
hemiarthroplasty had also undergone recent preoperative 
ITI. The patient had a painful haemophilic arthropathy 
with restricted ROM (abduction 45°, flexion 60° and 
outer rotation -10°), severe prolonged pain problems 
and an addiction to opiates. The surgery succeeded well 
under rFVIII coverage. The pain significantly diminished, 
and at the 7-mo follow-up, ROM substantially improved 
(abduction 80°/110° using scapulae, flexion 90°/130° 
using scapulae and outer rotation 45°) with pain-free 
peripheral movements. The X-rays showed a good 
position of the prosthesis. 
Revision arthroplasties
Two revision knee arthroplasties using reconstructive 
prostheses for Patient A were performed at 17.7 and 
15.7 years after primary operations because of loosening 
of the components. The hospital stay was 16 and 11 d, 
and CPM treatment was started three and five days after 
the operation, respectively. The postoperative mobility 
was 0°-100° and 0°-110° at 2.1 years and 1.8 years 
follow-up. After the first operation there was an initial 
bleed, but the joint outcome was good. The second 
operation and primary rehabilitation were successful 
with both good haemostatic and primary outcome. Five 
months postoperatively, a bacterial prepatellar bursitis 
was treated with peroral antibiotics. No deep infection 
was detected and the patient recovered well. 
The third knee revision arthroplasty was performed 
at 9 mo after a primary operation for Patient B because 
of loosening of the components. The patient had suffered 
from posttraumatic medial knee arthrosis, and the 
joint problem was considered primarily posttraumatic 
rather than haemophilic arthropathy. For these reasons, 
unicondylar knee replacement was performed. The 
loosening was thought to result from mechanical factors, 
but the compromised haemostasis by haemophilia 
may also play a role. Neither bacteria nor the signs of 
infection were detected. In spite of the fair haemostatic 
outcome, the joint outcome was good with 0°-110° 
ROM and freedom from pain at the 3.5-year follow-up. 
Radiologically, the components were in good position, 
and the walking ability had improved from 100 m to over 
one kilometre. 
Cost analysis
Since 2005 in Orton Orthopaedic Hospital, 11 major 
orthopaedic procedures (13 arthroplasties) on inhibitor 
patients were performed (Table 3). Among the high 
responder patients when aPCC and/or rFVIIa were 
needed, the total costs varied between 350900-500400 
Euros. In these cases, the replacement therapy covered 
the great majority, i.e., 87%-94%, of the total costs, 
even though two of the three operations were bilateral. 
Of the two low responders and in two cases among high 
responder patients after ITI, the replacement therapy 
costs were lower, being 59%-81% of the total costs. 
The total costs of these operations were also clearly 
lower compared to the high responders with an active 
inhibitor: About 1/5 - 1/3, i.e., 47200-103200 Euros, in 
the low responders and about 1/10, i.e., 43300-49800 
Euros, in the two high responders having undergone 
ITI. 
High responder patients with postoperative inhibitor 
formation had also a longer hospital stay (15-24 d) 
compared with the low responder patients (8-18 d) 
or the high responders with preoperative ITI (8-9 d). 
However, two of the three operations in high responder 
patients were also bilateral.
DISCUSSION
According to the guidelines of World Federation of 
Haemophilia[10], joint replacement surgery for haemo-
philia patients requires multidisciplinary teamwork. 
Despite the demanding surgery, good results among 
haemophilia patients with inhibitors have been previously 
reported[5-7,11-16]. However, there are only a few reports 
including joint arthroplasties on inhibitor patients[7,11,12,16-19] 
with scant follow-up data. As this is a rare patient group, 
randomised controlled trials are not - and are not likely - 
to become available.
In our report, the primary haemostatic outcome was 
good in half of the patients and poor in 20% of the high 
responder patients, and improved only with switching 
between the bypassing agents. However, the primary 
surgical outcome turned out fairly well, even in those 
patients who initially had a poor haemostatic outcome. 
Along prolonged rehabilitation, postoperative bleeding 
complications increase costs and reduce the patient’s 
Danielson H et al . Total joint replacement in inhibitor-positive haemophilia
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quality of life by increasing pain and disability. Every effort 
should focus on the avoidance of postoperative bleeds. 
Point of care monitoring with thromboelastography 
or a calibrated automated thrombogram may help in 
treatment decisions as the therapy unexpectedly may 
fail[20]. The therapy should be started preferentially 
with the bypassing agents, and the team should work 
intimately together with bedside visits to secure the 
haemostasis when the patient is to be mobilized. 
According to our experience, the use of cold to reduce 
swelling and pain may not be optimal, as cooling in the 
knee may impair the early haemostatic response. Finally, 
the tailored use of tranexamic acid, not only with rFVIIa 
but also with aPCC, may turn beneficial[21-23].
Radiosynovectomy has been shown to be an effective 
treatment in chronic haemophilic synovitis, diminishing 
pain and bleeding occurrence[24-26]. One of our patients 
had joint bleeds after TKR with only a temporary help 
from arthroscopical synovectomies. Even angiography 
was performed to exclude vascular anomalies, which 
have been reported in the form of pseudoaneurysms 
and their rupture after joint surgery or even natively[8]. 
Radiosynoviorthesis with Holmium isotope finally 
ended the bleeding episodes. The case is similar to 
Papavasiliou’s report[27] of successful radiosynovectomy 
after TKR, although that patient was not reported to have 
inhibitors. In our experience, radiosynoviorthesis seems 
to be effective also for patients who have undergone joint 
arthroplasty. 
The risk of infection (early- and late-onset) is known to 
be greater in haemophilia patients undergoing arthroplasty 
compared with the non-haemophilia population[21,28]. In 
our report there was one prepatellar bursitis, but deep 
infections were absent. However, the follow-up times were 
partly short. 
In one case, a unicondylar knee replacement was 
performed to a patient devoid of previous inhibitor 
history. The patient suffered from posttraumatic medial 
arthrosis and the primary hemostatic outcome was good. 
However, a rapid revision (9 mo postoperatively) was 
performed because of aseptic loosening of components. 
The loosening was thought to result from mechanical 
factors, but the compromised haemostasis by haemo-
philia may also play a role. In our experience, we do not 
recommend unicondylar arthroplasty to a patient with 
haemophilia. 
Surgery for patients with inhibitors is expensive and 
highly demanding. In our report, in 3/8 primary TKRs, 
revision-type (constrained or reconstructive) prostheses 
were used because of severe bone defects and soft 
tissue degeneration. According to our cost analysis, the 
operation itself including the components, surveillance, 
medication and hospital stay was less significant, 
whereas the major cost comprised of the haemostatic 
replacement therapy. This was especially evident among 
the high responder patients and when bypassing agents 
were needed, thus constituting ca. 90% of total costs. 
Instead, in high responder cases that had undergone 
preoperative ITI, the cost of replacement therapy was 
similar to the low responder patients’ cases and those 
of regular haemophilia management. The hospital stay 
was prolonged for the high responder patients, albeit two 
of the three operations were bilateral arthroplasties. In 
our opinion, preoperative ITI for high responder patients 
will bring cost and outcome benefits, both in surgery 
and the prevention of postoperative bleeds[29-31]. The 
disadvantages of ITI are its partial success rates and time 
constraints, under conditions where there is an urgent 
need for surgery. 
When determining the optimal timing for arthro-
plasty one must consider the grade of arthrosis, the 
patient’s age, the supposed survival of the chosen 
prosthesis, as well as the risk of complications. Also, 
working ability, the status of other joints, osteoporosis 
and the estimated overall prognosis are to be taken into 
account. For optimal prognosis, the operation should 
be performed before permanent joint contractures. 
From the haematological point of view, the patient 
Table 3  Cost analysis of arthroplasties on inhibitor patients since 2005
Resp Operation Component TOT eur HT2 eur HT (%)3 Product® Hospital stay(d)
Low Knee revision arthroplasty Unilateral Reconstructive 103200 75700 73 Kogenate Bayer 18
Low Knee revision arthroplasty Unilateral Reconstructive 95400 66900 70 Kogenate Bayer 11
Low Ankle arthroplasty Unilateral Primary ankle 47200 35600 75 Kogenate Bayer 10
Low Ankle arthroplasty Unilateral Primary ankle 60200 48800 81 Kogenate Bayer 12
Low Knee hemiarthroplasty Unilateral Unicondylar 51500 41600 81 Amofil 9
Low Knee revision arthroplasty Unilateral Cruciate retaining 50200 36300 72 Amofil 8
High Knee arthroplasty Bilateral Ps4 + hinge 350900 305500 87 Amofil 24
FEIBA
High Hip arthroplasty Unilateral Primary uncemented 43300 27800 64 ReFacto AF¹ 8
High Knee arthroplasty Bilateral Reconstructive 500400 445100 89 FEIBA 24
NovoSeven
High Knee arthroplasty Unilateral Ps4 409900 386100 94 FEIBA 15
NovoSeven
High Glenohumeral arthroplasty Unilateral Primary glenohumeral 49800 29300 59 ReFacto AF¹ 9
¹Successful preoperative ITI; 2HT haemophilia therapy (costs of replacement therapy); 3Procentual costs of replacement therapy; 4Ps posterior stabilized; 
Resp: Inhibitor responder (low = historical inhibitor titre < 5 BU/mL, high = historical inhibitor titre > 6 BU/mL).
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characteristics, plan for replacement therapy for surgery 
and rehabilitation must be meticulously evaluated 
preoperatively. An appropriate rehabilitation program 
prior to and after surgery takes into account other 
joints and their functionality during recovery in order 
not to induce other joint problems. In the surgery of 
haemophilia patients, especially with inhibitors, the 
comprehensive medical team has to observe the patient 
for early haemostatic symptoms and signs. Therefore, 
it is essential that these operations are centralized in a 
professional unit with the availability of skilled surgeons 
and haematologists having access to the bypassing 
agents and optimal laboratory tools. 
COMMENTS
Background
Total joint arthroplasty covered with coagulation factor replacement is the 
treatment of choice in severe haemophilic arthropathy. Inhibitor patients are 
especially challenging regarding not only the operation and haemostasis 
management but also the costs since the treatment can be very expensive. The 
aim was to collect data from joint replacement in inhibitor patients, evaluate 
haemostatic and patient outcomes, and analyse the costs.
Research frontiers
Despite the demanding surgery, good results among haemophilia patients with 
inhibitors have been previously reported. However, there are only a few reports 
including joint arthroplasties on inhibitor patients with scant follow-up data. 
Innovations and breakthroughs
In this report, the primary haemostatic outcome was good in half of the 
patients and poor in 20% of the high responder patients, and improved only 
with switching between the bypassing agents. However, the primary surgical 
outcome turned out fairly well, even in those patients who initially had a poor 
haemostatic outcome. In the authors’ opinion, preoperative immune-tolerance 
induction (ITI) for high responder patients will bring cost and outcome benefits, 
both in surgery and the prevention of postoperative bleeds. Also, in the authors’ 
experience, radiosynoviorthesis seems to be effective also for patients who 
have undergone joint arthroplasty. 
Applications
In the authors’ opinion, preoperative ITI for high responder patients will bring 
cost and outcome benefits, both in surgery and the prevention of postoperative 
bleeds. Also, in the authors' experience, radiosynoviorthesis seems to be 
effective also for patients who have undergone joint arthroplasty. Surgery 
of haemophilia patients should be centralized in a professional unit with the 
availability of skilled surgeons and haematologists having access to the 
bypassing agents and optimal laboratory tools. 
Terminology
ITI: With ITI therapy, factor concentrate is given regularly over a period of time 
until the body is trained to recognize the treatment product without reacting to it. 
Peer-review
The manuscript is written well.
ACKNOWLEDGMENTS
The authors thank Professor Vesa Rasi at the Red Cross 
Transfusion Central, Helsinki, Finland. He managed oper-
ations in the early part of the observation period.
REFERENCES
1 Webert KE, Rivard GE, Teitel J, Carcao M, Lillicrap D, St­Louis J, 
Walker IR. Low prevalence of inhibitor antibodies in the Canadian 
haemophilia population. Haemophilia 2012; 18: e254­e259 [PMID: 
22077390 DOI: 10.1111/j.1365­2516.2011.02694.x]
2 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia 
A: a systematic review. Haemophilia 2003; 9: 418­435 [PMID: 
12828678]
3 Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 
2006; 12 Suppl 6: 23­28; discussion 28­29 [PMID: 17123390 DOI: 
10.1111/j.1365­2516.2006.01362.x]
4 Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert 
SA, Waters J, Berntorp E; FENOC Study Group. A randomized 
comparison of bypassing agents in hemophilia complicated by an 
inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. 
Blood 2007; 109: 546­551 [PMID: 16990605 DOI: 10.1182/
blood­2006­04­017988]
5 Rodriguez-Merchan EC, Rocino A. Literature review of surgery 
management in inhibitor patients. Haemophilia 2004; 10 Suppl 2: 
22­29 [PMID: 15385043 DOI: 10.1111/j.1365­2516.2004.00937.x]
6 Quintana-Molina M, Martínez­Bahamonde F, González­García E, 
Romero­Garrido J, Villar­Camacho A, Jiménez­Yuste V, Fernández­
Bello I, Hernández­Navarro F. Surgery in haemophilic patients with 
inhibitor: 20 years of experience. Haemophilia 2004; 10 Suppl 2: 
30­40 [PMID: 15385044 DOI: 10.1111/j.1365­2516.2004.00938.x]
7 Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in high­
responder haemophilia patients. Haemophilia 2004; 10 Suppl 2: 46­49 
[PMID: 15385046 DOI: 10.1111/j.1365­2516.2004.00940.x]
8 Saarela MS, Tiitola M, Lappalainen K, Vikatmaa P, Pinomäki A, 
Alberty A, Lassila R. Pseudoaneurysm in association with a knee 
endoprothesis operation in an inhibitor­positive haemophilia A patient 
­ treatment with local thrombin. Haemophilia 2010; 16: 686­688 
[PMID: 20201962 DOI: 10.1111/j.1365­2516.2010.02205.x]
9 Mauser-Bunschoten EP, Zijl JA, Mali W, van Rinsum AC, van den 
Berg HM, Roosendaal G. Successful treatment of severe bleeding 
in hemophilic target joints by selective angiographic embolization. 
Blood 2005; 105: 2654­2657 [PMID: 15613551 DOI: 10.1182/
blood­2004­06­2063]
10 Wiedel J, Stabler S, Geraghty S,  Funk S. Joint replacement surgery in 
haemophilia. World Federation Haemophilia 2010; 50: 1­17
11 Rodriguez-Merchan EC, Jimenez­Yuste V, Gomez­Cardero P, 
Alvarez­Roman M, Martin­Salces M, Rodriguez de la Rua A. Surgery 
in haemophilia patients with inhibitors, with special emphasis on 
orthopaedics: Madrid experience. Haemophilia 2010; 16: 84­88 
[PMID: 20536990 DOI: 10.1111/j.1365­2516.2010.02223.x]
12 Rangarajan S, Yee TT, Wilde J. Experience of four UK 
comprehensive care centres using FEIBA® for surgeries in patients 
with inhibitors. Haemophilia 2011; 17: 28­34 [PMID: 20642787 DOI: 
10.1111/j.1365­2516.2010.02360.x]
13 Caviglia H, Candela M, Galatro G, Neme D, Moretti N, Bianco RP. 
Elective orthopaedic surgery for haemophilia patients with inhibitors: 
single centre experience of 40 procedures and review of the literature. 
Haemophilia 2011; 17: 910­919 [PMID: 21342367 DOI: 10.1111/
j.1365­2516.2011.02504.x]
14 Balkan C, Karapinar D, Aydogdu S, Ozcan C, Ay Y, Akin M, 
Kavakli K. Surgery in patients with haemophilia and high responding 
inhibitors: Izmir experience. Haemophilia 2010; 16: 902­909 [PMID: 
20518817 DOI: 10.1111/j.1365­2516.2010.02329.x]
15 Boadas A, Fernández­Palazzi F, De Bosch NB, Cedeño M, Ruiz­
Sáez A. Elective surgery in patients with congenital coagulopathies 
and inhibitors: experience of the National Haemophilia Centre of 
Venezuela. Haemophilia 2011; 17: 422­427 [PMID: 21118333 DOI: 
10.1111/j.1365­2516.2010.02427.x]
16 Jenkins PJ, Ekrol I, Lawson GM. Total knee replacement in patients 
with haemophilia: the Scottish experience. Scott Med J 2013; 58: 
223­227 [PMID: 24215041 DOI: 10.1177/0036933013507870]
17 Faradji A, Bonnomet F, Lecocq J, Grunebaum L, Desprez D, Kern 
Danielson H et al . Total joint replacement in inhibitor-positive haemophilia
 COMMENTS
784 October 18, 2017|Volume 8|Issue 10|WJO|www.wjgnet.com
O, Barbier L, Sibilia J. Knee joint arthroplasty in a patient with 
haemophilia A and high inhibitor titre using recombinant factor 
VIIa (NovoSeven): a new case report and review of the literature. 
Haemophilia 2001; 7: 321­326 [PMID: 11380637]
18 Hvid I, Rodriguez­Merchan EC. Orthopaedic surgery in haemophilic 
patients with inhibitors: an overview. Haemophilia 2002; 8: 288­291 
[PMID: 12010425]
19 Rodriguez-Merchan EC, Wiedel JD, Wallny T, Hvid I, Berntorp E, 
Rivard GE, Goddard NJ, Querol F, Caviglia H. Elective orthopaedic 
surgery for inhibitor patients. Haemophilia 2003; 9: 625­631 [PMID: 
14511305]
20 Dargaud Y, Lienhart A, Negrier C. Prospective assessment of 
thrombin generation test for dose monitoring of bypassing therapy 
in hemophilia patients with inhibitors undergoing elective surgery. 
Blood 2010; 116: 5734­5737 [PMID: 20810929 DOI: 10.1182/
blood­2010­06­291906]
21 Westberg M, Paus AC, Holme PA, Tjønnfjord GE. Haemophilic 
arthropathy: long­term outcomes in 107 primary total knee arthroplasties. 
Knee 2014; 21: 147­150 [PMID: 24156923 DOI: 10.1016/j.knee. 
2013.09.010]
22 Holmström M, Tran HT, Holme PA. Combined treatment with APCC 
(FEIBA®) and tranexamic acid in patients with haemophilia A with 
inhibitors and in patients with acquired haemophilia A­­a two­centre 
experience. Haemophilia 2012; 18: 544­549 [PMID: 22348384 DOI: 
10.1111/j.1365­2516.2012.02748.x]
23 Tran HT, Sørensen B, Rea CJ, Bjørnsen S, Ueland T, Pripp AH, 
Tjønnfjord GE, Holme PA. Tranexamic acid as adjunct therapy to 
bypassing agents in haemophilia A patients with inhibitors. Haemophilia 
2014; 20: 369­375 [PMID: 24251535 DOI: 10.1111/hae.12318]
24 Rampersad AG, Shapiro AD, Rodriguez­Merchan EC, Maahs JA, 
Akins S, Jimenez­Yuste V. Radiosynovectomy: review of the literature 
and report from two haemophilia treatment centers. Blood Coagul 
Fibrinolysis 2013; 24: 465­470 [PMID: 23492910 DOI: 10.1097/
MBC.0b013e3283602a28]
25 De la Corte-Rodriguez H, Rodriguez­Merchan EC, Jimenez­
Yuste V. Radiosynovectomy in hemophilia: quantification of its 
effectiveness through the assessment of 10 articular parameters. J 
Thromb Haemost 2011; 9: 928­935 [PMID: 21352468 DOI: 10.1111/
j.1538­7836.2011.04246.x]
26 Cho YJ, Kim KI, Chun YS, Rhyu KH, Kwon BK, Kim DY, Yoo MC. 
Radioisotope synoviorthesis with Holmium­166­chitosan complex 
in haemophilic arthropathy. Haemophilia 2010; 16: 640­646 [PMID: 
20148979 DOI: 10.1111/j.1365­2516.2009.02192.x]
27 Kapetanos GA, Papavasiliou KA, Makris V, Nikolaides AP, Kirkos 
JM, Symeonides PP. Recurrent spontaneous hemarthrosis after 
total knee arthroplasty successfully treated with synoviorthesis. J 
Arthroplasty 2008; 23: 931­933 [PMID: 18534524 DOI: 10.1016/
j.arth.2007.07.012]
28 Hirose J, Takedani H, Koibuchi T. The risk of elective orthopaedic 
surgery for haemophilia patients: Japanese single­centre experience. 
Haemophilia 2013; 19: 951­955 [PMID: 23746133 DOI: 10.1111/
hae.12209]
29 Ettingshausen CE, Kreuz W. The immune tolerance induction (ITI) 
dose debate: does the International ITI Study provide a clearer picture? 
Haemophilia 2013; 19 Suppl 1: 12­17 [PMID: 23278995 DOI: 
10.1111/hae.12051]
30 Scharf R, Kucharski W, Nowak T. Surgery in hemophilia A patients 
with factor VIII inhibitor: 10­year experience. World J Surg 1996; 20: 
1171­1181 [PMID: 8864078]
31 Gringeri A. VWF/FVIII concentrates in high­risk immunotolerance: 
the RESIST study. Haemophilia 2007; 13 Suppl 5: 73­77 [PMID: 
18078402 DOI: 10.1111/j.1365­2516.2007.01579.x]
P- Reviewer: Hasegawa M, Rattan V    S- Editor: Ji FF    L- Editor: A 
E- Editor: Lu YJ 
Danielson H et al . Total joint replacement in inhibitor-positive haemophilia
© 2017 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
